Search results for: CA 19-9 antibody, Monoclonal Antibodies, Host Mouse
#24029655 
2013/09/12
To Up
Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.
Despite their considerable advantages, many circulating biomarkers have well-documented limitations. One prominent shortcoming in oncology is a high frequency of false-positive indications for malignant disease in upfront diagnosis. Because one common cause of false positivism is biomarker production from benign disorders in unrelated host tissues, we hypothesized that probing the sites of biomarker secretion with an imaging tool could be a broadly useful strategy to deconvolute the meaning of foreboding but inconclusive circulating biomarker levels.Nerissa Therese Viola-Villegas, Samuel L Rice, Sean Carlin, Xiaohong Wu, Michael J Evans, Kuntal K Sevak, Marija Drobjnak, Govind Ragupathi, Ritsuko Sawada, Wolfgang W Scholz, Philip O Livingston, Jason S Lewis
2282 related Products with: Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.
100 U
Related Pathways
#18710355 //
To Up
Immunomodulation and pharmacological strategies in the treatment of graft-versus-host disease.
Allogeneic hematopoietic stem cell transplantation offers great promise for the treatment of a variety of diseases including malignancies and other diseases of hematopoietic origin. However, morbidity and mortality due to graft-versus-host disease (GVHD) remain a major barrier to its application.Minghui Li, Kai Sun, Lisbeth A Welniak, William J Murphy